This implies a wide therapy counteracting potential (NO-release, NO-synthase (NOS)-inhibition (L-NAME), NOS-over-activity (L-arginine), NO-system immobilization (L-NAME+L-arginine), i.e., in hypertension, hypotension, and thrombocytes function (without affecting coagulation cascade) [124,125,126,127,128,129,130,131], signaling pathways controlling vasomotor tone [121,122,123] (VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS)). The gene discussed is NOS2; the disease is hypertensive disorder.